Reactive oxygen species have been implicated in both the etiology and progression of diabetes complications, including nephropathy ([@B1]). However, clinical trials assessing the impact of antioxidant supplementation on micro- and macrovascular disease development have generally yielded null results ([@B2]).

It has recently been proposed that the effectiveness of an antioxidant regimen may be limited to susceptible subgroups, such as individuals with the haptoglobin (Hp) 2/2 genotype ([@B3]). Hp is an acute-phase plasma α~2~glycoprotein that, by binding to free Hb, inhibits Hb-induced oxidative tissue damage ([@B4]). Once bound to Hp, the Hp-Hb complex is cleared from circulation either at the liver hepatocyte or through the scavenger receptor CD163 present on monocytes and macrophages ([@B5]). In humans, two common allele classes (Hp^1^ and Hp^2^) at the Hp locus on chromosome 16q22 form three major genotypes: Hp 1/1, Hp 2/1, and Hp 2/2 ([@B4]). Substantial evidence supports a pathogenetic role of this polymorphism ([@B6]), with the Hp 1 protein allele being more efficient in preventing heme release from Hp-Hb complexes and promoting uptake by the CD163 macrophage receptor ([@B7][@B8]--[@B9]) as well as the antioxidant capacity of Hp 2 allele protein product being restricted by its greater molecular mass ([@B5]) and also associated with impaired reverse cholesterol transport ([@B7],[@B10]). Moreover, although Hp allele distribution does not differ by diabetes status ([@B6]), the Hp 2 allele protein product increases susceptibility to vascular complications only in diabetes ([@B11],[@B12]). Finally, daily vitamin E supplementation in type 2 diabetes with the Hp 2/2 genotype significantly reduced cardiovascular event risk ([@B13],[@B14]).

We have previously shown that the Hp 2/2 genotype is a determinant of the risk of cardiovascular disease also in type 1 diabetes ([@B15]). In this article, we evaluated the relationship between Hp genotype and both renal damage (microalbuminuria and macroalbuminuria) and renal function (end-stage renal disease \[ESRD\] and early renal function decline) in type 1 diabetes (*n* = 486).

RESEARCH DESIGN AND METHODS
===========================

The Epidemiology of Diabetes Complications Study was based on a historical cohort of incident cases of childhood-onset (\<17 years) type 1 diabetes, diagnosed or seen within 1 year of diagnosis (1950--1980) at Children\'s Hospital of Pittsburgh ([@B16]). The cohort has been shown to be representative of the Allegheny County, Pennsylvania, type 1 diabetes population ([@B17]). Subsequent to a first clinical assessment (1986--1988, when average participant age and diabetes duration were 28 and 19 years, respectively), biennial examinations were conducted for 10 years, with a further examination at 18 years. The University of Pittsburgh Institutional Review Board approved the study protocol.

Prior to each clinic visit, participants were sent questionnaires concerning demographic, health care, self-care, and medical history information. Blood pressure was measured with a random zero sphygmomanometer after a 5-min rest ([@B18]). Hypertension was defined as ≥140/90 mmHg or use of antihypertensive medication. Stable HbA~1~ was measured by ion exchange chromatography (Isolab, Akron, OH) and subsequently by automated highperformance liquid chromatography (Diamat; BioRad, Hercules, CA). The two assays were highly correlated (*r* = 0.95). HDL cholesterol was determined by a precipitation technique with a modification ([@B19]) of the Lipid Research Clinics method ([@B20]). Cholesterol and triglycerides were enzymatically measured ([@B21],[@B22]). Non-HDL cholesterol was calculated as total minus HDL cholesterol. White blood cell count was obtained using a counter S-plus IV and fibrinogen using a biuret colorimetric procedure and a clotting method.

Urinary albumin was measured by immunonephelometry ([@B23]), and creatinine was assayed by an Ectachem 400 Analyzer (Eastman Kodak, Rochester, NY). Microalbuminuria was defined as albumin excretion rate (AER) of 20--200 μg/min (30--300 mg per 24 h) and macroalbuminuria as AER \>200 μg/min (\>300 mg per 24 h) in at least 2 of 3 validated timed urine collections. In 10% of the samples, urine collections were deemed inadequate based on creatinine excretion and albumin-to-creatinine ratio was used (microalbuminuria, 0.03--0.3 mg/mg; macroalbuminuria, \>0.3 mg/mg) ([@B24]). ESRD onset was defined as starting dialysis or undergoing renal transplantation. Early renal function decline was defined as the incidence of a decline of ≥30 ml/min per 1.73 m^2^ from baseline estimated glomerular filtration rate (eGFR) based on the Cockcroft-Gault equation ([@B25]) among participants with normal or mildly reduced renal function at study entry (stages I and II).

High molecular weight genomic DNA was isolated using the PureGene kit (Gentra Systems, Minneapolis, MN), and Hp was genotyped by an amplification method ([@B26]). Genotypes were assigned visually by comparison with controls of known genotype and in a random sample showed excellent agreement (97%) with an Eliza method ([@B27]).

Statistical analysis.
---------------------

Nonnormally distributed variables were logarithmically transformed. Univariate associations were determined using the Student *t* test and χ^2^ or Fisher exact test, as appropriate. Cox proportional hazards models with backward elimination were constructed to assess the multivariable association between Hp genotype and the incidence of each outcome of interest adjusting for traditional risk factors (including eGFR and AER levels at study entry) and univariately significant variables. Survival time was defined as the time in years from study entry to either an incident event or censorship during the 18-year follow-up. Statistical analyses were conducted using SAS (version 9.1; SAS Institute, Cary, NC).

RESULTS
=======

Of 658 study participants, DNA for Hp genotyping was available for 486 (73.9%). Compared with those without DNA available, individuals with DNA data had a shorter diabetes duration and higher HbA~1~, blood pressure, non-HDL cholesterol, serum creatinine, eGFR, and AER. The distribution of the Hp genotype was 12.1% Hp 1/1, 44.4% Hp 2/1, and 43.4% Hp 2/2. Generally, no differences were observed in participant characteristics by Hp genotype at study entry with the exception of younger age and higher non-HDL cholesterol in those with the Hp 2/2 compared with the 2/1 genotype and lower insulin dose per weight in those with the Hp 2/1 compared with the 1/1 genotype.

During 18 years of follow-up, 40.5% (*n* = 111) developed incident microalbuminuria, 16.7% (*n* = 62) macroalbuminuria, and 12.2% (*n* = 58) ESRD. Moreover, 188 (42.0%) exhibited an early decline in renal function (≥30 ml/min per 1.73 m^2^ from baseline eGFR). Descriptive participant characteristics by incidence of microalbuminuria and macroalbuminuria are shown in [Table 1](#T1){ref-type="table"} and by renal function decline ≥30 ml/min per 1.73 m^2^ and ESRD incidence in [Table 2](#T2){ref-type="table"}. Generally, incident case subjects with both microalbuminuria and macroalbuminuria were more likely to have higher levels of HbA~1~, non-HDL cholesterol, AER, and inflammatory markers compared with those who remained disease free. Incident case subjects with macroalbuminuria were also older at the time of diabetes onset compared with noncase subjects and had a greater waist-to-hip ratio.

###### 

Participant characteristics at study entry by subsequent microalbuminuria and macroalbuminuria status

                                                                          Microalbuminuria       Macroalbuminuria                                                                                            
  ----------------------------------------------------------------------- ---------------------- ---------------------- -------------------------------------- ---------------------- ---------------------- --------------------------------------
  *n*                                                                     163                    111                                                           309                    62                     
  Age (years)                                                             25.0 ± 7.7             25.8 ± 8.3             0.37                                   26.2 ± 8.1             27.1 ± 7.4             0.43
  Age at onset (years)                                                    8.5 ± 4.2              8.3 ± 4.1              0.64                                   8.2 ± 4.2              9.3 ± 3.3              0.02
  Diabetes duration (years)                                               16.3 ± 6.9             17.6 ± 7.6             0.21                                   18.0 ± 7.6             17.8 ± 7.5             0.83
  Follow-up time (years)                                                  15.5 ± 5.0             7.3 ± 4.8              \<0.0001                               15.2 ± 5.0             8.0 ± 5.3              \<0.0001
  Female subjects                                                         50.9 (83)              55.9 (62)              0.42                                   52.4 (162)             40.3 (25)              0.08
  BMI (kg/m^2^)                                                           23.1 ± 3.2             23.2 ± 3.3             0.70                                   23.5 ± 3.4             23.6 ± 3.1             0.74
  Waist-to-hip ratio                                                      0.81 ± 0.06            0.82 ± 0.06            0.27                                   0.81 ± 0.07            0.84 ± 0.07            0.002
  Ever smokers                                                            28.8 (47)              31.5 (35)              0.63                                   32.0 (99)              38.7 (24)              0.31
  HbA~1~ (%)                                                              9.7 (1.4)              10.8 (1.8)             \<0.0001                               10.0 (1.6)             11.1 (2.0)             0.0002
  Insulin dose per weight[\*](#TF1-1){ref-type="table-fn"}                0.81 (0.65--0.95)      0.80 (0.66--0.95)      0.77                                   0.80 (0.63--0.94)      0.80 (0.60--0.98)      0.97
  Systolic blood pressure (mmHg)                                          106.9 ± 10.7           109.1 ± 10.3           0.10                                   108.8 ± 11.4           110.7 ± 12.9           0.24
  Diastolic blood pressure (mmHg)                                         67.9 ± 8.4             69.8 ± 7.8             0.05                                   69.5 ± 9.1             70.8 ± 9.1             0.31
  Hypertension                                                            3.7 (6)                3.6 (4)                1.00[†](#TF1-2){ref-type="table-fn"}   5.5 (17)               9.7 (6)                0.21
  HDL cholesterol (mg/dl)                                                 55.2 ± 12.1            54.0 ± 9.8             0.37                                   54.5 ± 11.4            56.1 ± 11.9            0.38
  Non-HDL cholesterol (mg/dl)                                             116.0 ± 25.5           128.1 ± 34.3           0.002                                  122.9 ± 30.2           141.1 ± 43.2           0.002
  ACE/ARB use                                                             1.3 (2)                0.9 (1)                1.00[†](#TF1-2){ref-type="table-fn"}   1.0 (3)                1.7 (1)                0.52[†](#TF1-2){ref-type="table-fn"}
  Serum creatinine (mg/dl)[\*](#TF1-1){ref-type="table-fn"}               0.80 (0.70--1.0)       0.80 (0.60--0.90)      0.16                                   0.80 (0.70--1.0)       0.90 (0.70--1.0)       0.39
  eGFR by Cockcroft-Gault (ml/min per 1.73 m^2^)                          121.1 ± 37.8           124.6 ± 38.7           0.46                                   120.9 ± 37.1           125.0 ± 43.5           0.44
  AER (μg/min)[\*](#TF1-1){ref-type="table-fn"}                           7.2 (5.1--10.1)        9.0 (6.2--11.6)        0.004                                  19.2 (5.9--16.1)       23.5 (9.5--71.3)       \<0.0001
  White blood cell count × 10^3^/mm^2^[\*](#TF1-1){ref-type="table-fn"}   5.6 (4.8--6.6)         6.1 (5.2--7.2)         0.02                                   5.8 (5.1--7.0)         6.7 (5.2--8.0)         0.005
  Fibrinogen (mg/dl)[\*](#TF1-1){ref-type="table-fn"}                     250.0 (200.0--300.0)   265.0 (220.0--300.0)   0.12                                   250.0 (210.0--305.0)   270.0 (240.0--310.0)   0.06
  Hp genotype                                                                                                                                                                                                
      1/1                                                                 77.4 (24)              22.6 (7)                                                      81.4 (35)              18.6 (8)               
      2/1                                                                 55.5 (71)              44.5 (57)                                                     84.8 (145)             15.2 (26)              
      2/2                                                                 59.1 (68)              40.9 (47)              0.08                                   82.2 (129)             17.8 (28)              0.77

Data are percent (*n*) or means ± SD unless otherwise indicated. The sample size for ACE/angiotensin receptor blocker medications was 270 for the outcome of microalbuminuria (159 noncases and 111 incident cases) and 362 for the outcome of macroalbuminuria (302 noncases and 60 incident cases).

\*The Wilcoxon two-sample test was used for nonnormally distributed variables; data are median (interquartile range).

†Fisher exact test. ARB, angiotensin receptor blocker.

###### 

Participant characteristics at study entry by a subsequent decline ≥30 ml/min per 1.73 m^2^ from baseline eGFR and ESRD

                                                                          A decline ≥30 ml/min per 1.73 m^2^ from baseline eGFR   ESRD                                                                                                            
  ----------------------------------------------------------------------- ------------------------------------------------------- ---------------------- -------------------------------------- ---------------------- -------------------------- ----------
  *n*                                                                     260                                                     188                                                           416                    58                         
  Age (years)                                                             26.2 ± 8.0                                              27.8 ± 7.3             0.04                                   26.6 ± 7.8             31.2 ± 6.3                 \<0.0001
  Age at onset (years)                                                    7.9 ± 4.2                                               9.0 ± 3.8              0.005                                  8.4 ± 4.1              7.8 ± 3.9                  0.29
  Diabetes duration (years)                                               18.3 ± 7.3                                              18.8 ± 7.6             0.53                                   18.2 ± 7.4             23.4 ± 7.1                 \<0.0001
  Follow-up time (years)                                                  14.0 ± 5.3                                              6.5 ± 4.8              \<0.0001                               15.2 ± 3.9             9.1 ± 4.6                  \<0.0001
  Female subjects                                                         45.8 (119)                                              54.3 (102)             0.08                                   49.5 (206)             48.3 (28)                  0.86
  BMI (kg/m^2^)                                                           23.3 ± 3.5                                              24.3 ± 3.0             0.0008                                 23.6 ± 3.3             23.9 ± 3.0                 0.48
  Waist-to-hip ratio                                                      0.82 ± 0.07                                             0.83 ± 0.07            0.47                                   0.82 ± 0.07            0.84 ± 0.08                0.09
  Ever smokers                                                            33.5 (87)                                               38.8 (73)              0.24                                   34.6 (144)             41.4 (24)                  0.31
  HbA~1~ (%)                                                              8.5 (1.4)                                               9.0 (1.4)              0.0004                                 10.2 (1.7)             10.6 (1.9)                 0.11
  Insulin dose per weight[\*](#TF3-1){ref-type="table-fn"}                0.80 (0.62--0.94)                                       0.77 (0.64--0.94)      0.75                                   0.80 (0.64--0.94)      0.67 (0.57--0.80)          0.002
  Systolic blood pressure (mmHg)                                          110.6 ± 12.6                                            113.4 ± 14.9           0.04                                   110.7 ± 12.8           123.5 ± 16.5               \<0.0001
  Diastolic blood pressure (mmHg)                                         71.1 ± 10.5                                             72.7 ± 10.8            0.10                                   71.1 ± 10.2            77.9 ± 12.4                0.0001
  Hypertension                                                            9.6 (25)                                                13.8 (26)              0.17                                   9.1 (38)               50.0 (29)                  \<0.0001
  HDL cholesterol (mg/dl)                                                 55.2 ± 12.4                                             52.9 ± 11.4            0.05                                   54.6 ± 12.1            50.2 ± 10.4                0.009
  Non-HDL cholesterol (mg/dl)                                             127.5 ± 34.2                                            138.9 ± 44.2           0.003                                  128.8 ± 34.9           166.5 ± 57.6               \<0.0001
  ACE/ARB use                                                             1.6 (4)                                                 2.2 (4)                0.47[†](#TF3-2){ref-type="table-fn"}   1.5 (6)                13.8 (8)                   \<0.0001
  Serum creatinine (mg/dl)[\*](#TF3-1){ref-type="table-fn"}               0.90 (0.80--1.10)                                       0.70 (0.60--0.90)      \<0.0001                               0.80 (0.70--1.0)       1.3 (0.90--1.80)           \<0.0001
  eGFR by Cockcroft-Gault (ml/min per 1.73 m^2^)                          105.3 ± 23.4                                            140.6 ± 42.9           \<0.0001                               121.3 ± 38.0           77.7 ± 40.8                \<0.0001
  AER (μg/min)[\*](#TF3-1){ref-type="table-fn"}                           10.6 (6.2--31.0)                                        19.6 (8.8--363.1)      \<0.0001                               11.3 (6.8--46.7)       1,030.2 (281.5--1,877.8)   \<0.0001
  White blood cell count × 10^3^/mm^2^[\*](#TF3-1){ref-type="table-fn"}   6.1 (5.2--7.1)                                          6.2 (5.4--7.6)         0.10                                   6.1 (5.2--7.2)         7.1 (5.9--8.9)             \<0.0001
  Fibrinogen (mg/dl)[\*](#TF3-1){ref-type="table-fn"}                     250.0 (210.0--310.0)                                    270.0 (240.0--350.0)   0.0007                                 270.0 (220.0--310.0)   310.0 (270.0--390.0)       \<0.0001
  Hp genotype                                                                                                                                                                                                                                     
      1/1                                                                 64.8 (35)                                               35.2 (19)                                                     87.9 (51)              12.1 (7)                   
      2/1                                                                 62.1 (128)                                              37.9 (78)                                                     90.2 (193)             9.8 (21)                   
      2/2                                                                 51.6 (97)                                               48.4 (91)              0.06                                   85.2 (172)             14.9 (30)                  0.29

Data are percent (*n*) or means ± SD unless otherwise indicated. The sample size for ACE/angiotensin receptor blocker medications was 437 for a decline ≥30 ml/min per 1.73 m^2^ from baseline eGFR (251 noncases and 186 incident cases) and 463 for the outcome of ESRD (405 noncases and 58 incident cases).

\*The Wilcoxon two-sample test was used for nonnormally distributed variables; data are median (interquartile range).

†Fisher exact test. ARB, angiotensin receptor blocker.

Compared with noncase subjects, incident case subjects with early renal function decline and ESRD were older, with higher systolic blood pressure, non-HDL cholesterol, AER, and inflammatory marker levels and lower HDL cholesterol. Incident case subjects with early renal function decline had an older age of diabetes onset and higher BMI, HbA~1~, and eGFR and lower serum creatinine. Conversely, greater diabetes duration and higher levels of diastolic blood pressure and serum creatinine but lower insulin dose per kilogram body weight and eGFR were observed in incident case subjects with ESRD compared with noncase subjects. No univariate association, however, was observed between Hp and the incidence of other renal outcomes at the 0.05 significance level. Hp genotype was also not associated with all-cause mortality (*P* = 0.80) based on 82 (16.9%) deceased individuals.

Multivariable Cox proportional hazards models ([Table 3](#T3){ref-type="table"}) showed no association between the Hp genotype and microalbuminuria or macroalbuminuria incidence. Conversely, adjusting for univariately significant risk factors, an increased risk of an early renal function decline was observed for individuals carrying the Hp 2/2 compared with the Hp 1/1 genotype (hazard ratio 1.79 \[95% CI = 1.06--3.00\]). Similarly, the Hp 2/2 conferred over a twofold increased risk of ESRD compared with the Hp 1/1 genotype (2.45 \[1.05--5.73\]). The risk associated with the Hp 2/1 reached statistical significance for neither early renal function decline nor ESRD incidence.

###### 

Hazard ratios (95% CIs) from Cox proportional hazard models for the incidence of microalbuminuria, macroalbuminuria, eGFR decline (decline ≥30 ml/min per 1.73 m^2^ from baseline eGFR), and ESRD

  Outcome                                                                                                                    Crude               Model 1              Model 2             Model 3
  -------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------- ------------------- -------------------
  Microalbuminuria (*n* = 270, 111 incident events)                                                                                                                                       
  Hp genotype                                                                                                                                                                             
      1/1                                                                                                                    Referent            Referent             Referent            Referent
      2/1                                                                                                                    2.09 (0.95--4.59)   2.19 (0.996--4.80)   2.08 (0.95--4.56)   1.77 (0.80--3.92)
      2/2                                                                                                                    1.84 (0.83--4.07)   1.95 (0.88--4.32)    1.67 (0.75--3.71)   1.34 (0.59--3.05)
      A1C                                                                                                                    1,147.803           1,140.392            1,106.418           1,100.600
  Model 1 allowed for diabetes duration, sex, log AER, and eGFR                                                                                                                           
  Model 2 allowed for variables in model 1 in addition to HbA~1~, systolic blood pressure, and HDL and non-HDL cholesterol                                                                
  Model 3 allowed for variables in model 2 in addition to white blood cell count                                                                                                          
  Macroalbuminuria (*n* = 364, 61 incident events)                                                                                                                                        
  Hp genotype                                                                                                                                                                             
      1/1                                                                                                                    Referent            Referent             Referent            Referent
      2/1                                                                                                                    0.77 (0.35--1.70)   0.78 (0.35--1.72)    0.77 (0.35--1.72)   0.72 (0.33--1.60)
      2/2                                                                                                                    0.84 (0.38--1.86)   0.78 (0.35--1.72)    0.78 (0.35--1.73)   0.73 (0.33--1.62)
      A1C                                                                                                                    686.874             656.057              640.020             636.806
  Model 1 allowed for diabetes duration, sex, smoking status, waist-to-hip ratio, log AER, and eGFR                                                                                       
  Model 2 allowed for variables in model 1 in addition to HbA~1~, systolic blood pressure, and HDL and non-HDL cholesterol                                                                
  Model 3 allowed for variables in model 2 in addition to white blood cell count                                                                                                          
  A decline ≥30 ml/min per 1.73 m^2^ from baseline eGFR (*n* = 441, 187 incident events)                                                                                                  
  Hp genotype                                                                                                                                                                             
      1/1                                                                                                                    Referent            Referent             Referent            Referent
      2/2                                                                                                                    1.59 (0.97--2.60)   1.30 (0.78--2.18)    1.38 (0.82--2.31)   1.38 (0.82--2.31)
      2/2                                                                                                                    1.59 (0.97--2.60)   1.64 (0.99--2.73)    1.79 (1.06--3.00)   1.79 (1.06--3.00)
      A1C                                                                                                                    2,102.198           1,897.376            1,896.567           1,896.567
  Model 1 allowed for diabetes duration, sex, BMI, log AER, and eGFR                                                                                                                      
  Model 2 allowed for variables in model 1 in addition to HbA~1~, systolic blood pressure, and HDL and non-HDL cholesterol                                                                
  Model 3 allowed for variables in model 2 in addition to fibrinogen                                                                                                                      
  ESRD (*n* = 467, 57 incident events)                                                                                                                                                    
  Hp genotype                                                                                                                                                                             
      1/1                                                                                                                    Referent            Referent             Referent            Referent
      2/1                                                                                                                    0.72 (0.30--1.69)   1.14 (0.48--2.74)    1.24 (0.51--2.98)   1.32 (0.55--3.16)
      2/2                                                                                                                    1.15 (0.50--2.61)   2.17 (0.93--5.04)    2.74 (1.17--6.45)   2.45 (1.05--5.73)
      A1C                                                                                                                    672.450             522.184              509.657             508.736
  Model 1 allowed for diabetes duration, sex, smoking status, log AER, and eGFR                                                                                                           
  Model 2 allowed for variables in model 1 in addition to HbA~1~, hypertension, and HDL and non-HDL cholesterol                                                                           
  Model 3 allowed for variables in model 2 in addition to white blood cell count and fibrinogen                                                                                           

To examine the possibility of survival bias, we stratified the cohort by diabetes diagnosis year (prior to or after 1965, wherein mortality was 40 vs. 13%, respectively). With the exception of macroalbuminuria, a trend toward higher incidence rates among the Hp 2/2 compared with the Hp 1/1 genotype was generally observed in those diagnosed after 1965 (less subject to survival bias); however, none of the stratified results were statistically significant ([Table 4](#T4){ref-type="table"}). Similarly, when conducting cumulative incidence analyses (including prevalent cases in outcomes), results demonstrated nonsignificantly higher rates in those carrying the Hp 2/2 compared with the Hp 1/1 genotype with the exception of macroalbuminuria ([Table 4](#T4){ref-type="table"}).

###### 

Incidence of renal outcomes by Hp genotype

  Outcome incidence               *n*   Hp genotype   *P*                       
  ------------------------------- ----- ------------- ------------ ------------ ---------------------------------------
  Microalbuminuria                                                              
      Diabetes diagnosis ≤1965    73    11.1 (1)      46.3 (19)    47.8 (11)    0.14[\*](#TF4-1){ref-type="table-fn"}
      Diabetes diagnosis \>1965   201   27.3 (6)      43.7 (38)    39.1 (36)    0.37
      Total cohort                274   22.6 (7)      44.5 (57)    40.9 (47)    0.08
      Cumulative incidence        483   59.3 (35)     67.1 (145)   67.3 (140)   0.49
  Macroalbuminuria                                                              
      Diabetes diagnosis ≤1965    112   0.0 (0)       17.5 (11)    24.3 (9)     0.16[\*](#TF4-1){ref-type="table-fn"}
      Diabetes diagnosis \>1965   259   25.8 (8)      13.9 (15)    15.8 (19)    0.28
      Total cohort                371   18.6 (8)      15.2 (26)    17.8 (28)    0.77
      Cumulative incidence        483   40.7 (24)     32.9 (71)    38.0 (79)    0.40
  Early renal function decline                                                  
      Diabetes diagnosis ≤1965    145   47.1 (8)      34.3 (25)    50.9 (28)    0.15
      Diabetes diagnosis \>1965   303   29.7 (11)     39.9 (53)    47.4 (63)    0.13
      Total cohort                448   35.2 (19)     37.9 (78)    48.4 (91)    0.06
  ESRD                                                                          
      Diabetes diagnosis ≤1965    162   22.2 (4)      17.7 (14)    27.7 (18)    0.33[\*](#TF4-1){ref-type="table-fn"}
      Diabetes diagnosis \>1965   312   7.5 (3)       5.2 (7)      8.8 (12)     0.50[\*](#TF4-1){ref-type="table-fn"}
      Total cohort                474   12.1 (7)      9.8 (21)     14.9 (30)    0.29
      Cumulative incidence        483   13.6 (8)      10.7 (23)    17.3 (36)    0.14

Data are percent (*n*) unless otherwise indicated.

\*Fisher exact test.

DISCUSSION
==========

In this cohort of subjects with type 1 diabetes, we failed to show an association between the Hp genotype and either microalbuminuria or macroalbuminuria incidence. However, although not univariately significant, approximately a twofold increased risk emerged for outcomes assessing renal function decline and ESRD incidence after multivariable adjustments.

Previous studies assessing the association between the Hp phenotype and the presence or incidence of renal disease have produced discrepant findings. In a small, cross-sectional study of normotensive subjects with type 1 or 2 diabetes, none of those with the Hp 1/1 phenotype exhibited signs of nephropathy (0/18) compared with 27% (10/37) of those with Hp 2/1 and 34% (19/55) of those with Hp 2/2 (*P* \< 0.02) ([@B6],[@B28]). Similar results were reported from an Irish type 1 diabetes case-control study ([@B29]). Conversely, a Japanese study of individuals with a long duration (\>10 years) of type 2 diabetes did not observe an increased risk associated with the common Hp phenotype (*P* = 0.43) ([@B30]). Similarly, we were also not able to detect an association for either microalbuminuria or macroalbuminuria incidence in our cohort of individuals with a long duration of type 1 diabetes, perhaps suggesting that at a more advanced stage of diabetes, early Hp-susceptible cases of microalbuminuria and macroalbuminuria may have been excluded. Indeed, the cumulative incidence of microalbuminuria (including both prevalent cases at study entry and incident cases) appeared higher in our study among participants carrying the Hp 2 allele, although results did not reach statistical significance. However, analogous findings were not observed for the cumulative incidence of macroalbuminuria, suggesting that the Hp 2/2 genotype is not a strong determining factor for progression to macroalbuminuria.

Despite the null associations for the incidence of proteinuria, a strong relationship was noted between the Hp 2/2 genotype and the incidence of both an early decline in renal function and ESRD. Unfortunately, we are not aware of any published reports on the association between the Hp genotype and renal function decline among individuals with diabetes and thus cannot, at present, confirm these findings. However, the possibility of a factor affecting the incidence of renal dysfunction but not that of renal disease per se raises the hypothesis that these are two different disease entities, and thus factors contributing to their development may be distinct. Indeed, almost a decade ago, we suggested that in certain cases tubulopathy may precede glomerulopathy in type 1 diabetes and that even microalbuminuria may be secondary to impaired tubular reabsorption ([@B31]). More recently, research studies have shown that reductions in eGFR do occur without preceding microalbuminuria in those with diabetes ([@B32][@B33]--[@B34]). Importantly, a pathophysiological mechanism has been proposed that could account for the increased rate of renal function decline among individuals with diabetes and the Hp 2/2 genotype ([@B7]), based on the recognition that renal proximal tubule cells serve as a (secondary to CD163) default mechanism for clearance of the Hp-Hb complex. Because CD163-mediated clearance of the Hp-Hb complex is impaired in subjects with diabetes and the Hp 2/2 genotype, renal proximal tubule cells are used to a greater extent, resulting in a dramatic increase in iron deposition, oxidative stress, and hypertrophy. In fact, Hp 2/2 diabetic mice have been shown to display significantly increased glomerular and proximal tubular hypertrophy and greater deposition of collagen type IV, smooth muscle actin, and increased renal iron ([@B35]). Intriguingly, vitamin E administration was shown to slow diabetic renal disease progression among the Hp 2/2 but not the Hp 1/1 mice.

In conclusion, we observed an association between the Hp genotype and renal function decline in individuals with long-standing type 1 diabetes. A caveat of this study is the lack of independent replication of findings in another cohort. Nevertheless, these results raise the possibility that pharmacological administration of vitamin E, shown to reduce cardiovascular disease outcomes in those with type 2 diabetes with the Hp 2/2 genotype ([@B13]--[@B14]), may also lead to reduced renal disease risk.
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